Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients (Q41013973)

25 September 2017

1 reference

title

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients (English)

1 reference

25 September 2017

R N Jones

1

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

100

1 reference

25 September 2017

issue

6A

1 reference

25 September 2017

page(s)

3S-12S

1 reference

An overview of nosocomial infections, including the role of the microbiology laboratory

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Major trends in the microbial etiology of nosocomial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

The national nosocomial infections surveillance system: Plans for the 1990s and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Staphylococcus epidermidis: a significant nosocomial pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Emergence of vancomycin resistance in coagulase-negative staphylococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Genetics and mechanisms of glycopeptide resistance in enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Origin and impact of plasmid-mediated extended-spectrum beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

beta-Lactamases of gram-negative bacteria: new challenges for new drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

New mechanisms of bacterial resistance to antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Transferable imipenem resistance in Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

A new therapeutic option for the treatment of pneumonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

In vitro killing of penicillin-suseceptible, -intermediate, and -resistant strains of streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: A comparison of bactericidal and inhibitory activity with achievable CSF levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

USA resistance patterns among UTI pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Review of the in vitro spectrum of activity of imipenem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

In-vitro studies of meropenem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Current and future management of serious skin and skin-structure infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

Emergence of coagulase negative staphylococci as major nosocomial bloodstream pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900102-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(96)00102-7

1 reference

25 September 2017

1 reference